Ascentage Pharma Group
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Ascentage Pharma Group sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Ascentage Pharma Group: 15 sponsored US clinical trials, 8 recruiting.
Ascentage Pharma Group sponsors 15 registered US clinical trials on ClinicalTrials.gov, 8 of them currently recruiting, and 4 completed. 4 of these trials are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is CLL/SLL, with 2 trials.
Top-decile sponsor footprint
Ascentage Pharma Group ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
15 total, page 1 of 1
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
NCT06641414
Study of Olverembatinib (HQP1351) in Patients With CP-CML
NCT06423911
Global Trial in APG2575 for Patients With CLL/SLL
NCT06104566
A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)
NCT06051409
A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL
NCT04496349
Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL/SLL
NCT04215809
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
NCT04260022
APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies
NCT03537482
A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT03611868
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
NCT07424833
APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia
NCT04260217
Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung Cancer
NCT04210037
APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies
NCT03386526
A Study of APG-1252 in Patients With SCLC or Other Solid Tumors
NCT03080311
APG-115 in Patients With Advanced Solid Tumors or Lymphomas
NCT02935907
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 10 |
| Phase 2 | 1 |
| Phase 3 | 4 |
Therapeutic Areas
What is open in the Ascentage Pharma Group pipeline
8 recruiting of 15 indexed (53% open); 4 completed (27%).
Phase mix: 4 late (III/IV) vs 11 early (I/II) (early-phase heavy).
Top condition: CLL/SLL (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ascentage Pharma Group: open-pipeline peers nationwide
Peers matched on 15 registered trials and 53% open enrollment, not the therapeutic-area sidebar.
Ascentage Pharma Group sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 trials (± recruiting share)
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors near 53% open enrollment (± trial volume)
- Children's Hospital of Orange County · 54% recruiting · 13 trials
- University of Notre Dame · 54% recruiting · 13 trials
- Disc Medicine · 56% recruiting · 9 trials
- Heart Rhythm Clinical and Research Solutions · 56% recruiting · 9 trials
Related
What to do with this Ascentage Pharma Group page
15 registered trials is a research-attention snapshot, not an endorsement of Ascentage Pharma Group or any single study.
- 8 of Ascentage Pharma Group's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- CLL/SLL is the condition Ascentage Pharma Group studies most, compare against other sponsors active in the same condition before evaluating a specific study. See CLL/SLL trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Ascentage Pharma Group pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.